Empagduo Tablet 12.5/500 mg
Empagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
MFDS item code 202302647 · Approved 2023.09.05
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medication is used in conjunction with dietary and exercise therapies to help control blood sugar in adult patients with type 2 diabetes. It contains both empagliflozin and metformin, enhancing the blood sugar control effect, especially suitable for cases where blood sugar is not adequately controlled. Moreover, attention is needed for patients with cardiovascular diseases, hence clinical trial information for related professionals should be referred to. This medication is effective in improving blood sugar control.
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who are unable to achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose of 10 mg) and the patient’s existing dose of metformin. If the patient tolerates empagliflozin 10 mg (total daily dose) well but requires additional glycemic control, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose of 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see sections 4. Adverse Reactions and 6. Drug Interactions in Precautions for Use). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take a double dose at one time; in this case, skip the missed dose. Special populations Patients with renal impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who have no other condition that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual single-ingredient products of empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be carefully monitored every 3-6 months (see section 1) under section 3. Caution in administration to the following patients in Precautions for Use). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, discontinue this medicine immediately (see section 2) under section 2. Do not administer to the following patients in Precautions for Use). Elderly patients In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This medication assists in the regulation of blood sugar. However, caution is needed as a rare side effect known as severe lactic acidosis may occur. Care should be taken if taken with other diabetes medications, as hypoglycemia may happen. This medication should not be used in certain patients. For instance, individuals with allergies to this drug or its components, those with severely impaired kidney function, acute infections, or dehydration should not take it. Additionally, individuals with type 1 diabetes or acute metabolic acidosis, as well as pregnant or breastfeeding women, should not take this medication. Patients with slightly impaired kidney function or at risk of fluid loss should use this medication cautiously. In particular, when used with insulin or sulfonylureas, dosage adjustments may be needed to reduce the risk of hypoglycemia. Irregular meals, intense exercise, and interactions with other drugs should also be monitored. Side effects such as hypoglycemia, urinary tract infections, genital infections, increased urination, gastrointestinal disturbances may occur when taking this medication. In particular, caution is needed, especially when used with insulin, as this can increase the risk of hypoglycemia. Lactic acidosis is a rare but very serious side effect; symptoms such as fatigue, muscle pain, difficulty breathing, or abdominal pain should prompt immediate medical attention. Additionally, metabolic issues like ketoacidosis can occur, requiring immediate treatment if symptoms such as vomiting, loss of appetite, abdominal pain, or difficulty breathing arise. This medication may affect body hydration status, so patients at risk for dehydration or hypotension should be particularly cautious. Patients with poor liver function or heart failure should consult a doctor before taking this medication. Pregnant or breastfeeding women should not take this medication, and it is not recommended for children under 18 years of age. Elderly patients may have a risk of reduced kidney function, so regular testing is required, and dosage adjustments may be necessary. In case of overdose, there is a risk of lactic acidosis, so immediate medical treatment is required, and blood dialysis may be necessary. This medication should be stored out of reach of children and kept in its original container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent exposure to air or moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius (room temperature).
Biconvex oval film-coated tablet with a light brownish-purple color
60 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/box [10 tablets/PTP x 6]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Kujoo Pharmaceutical Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 12.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Boehringer Ingelheim Korea Co., Ltd.
CombinationEmpagliflozin 5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Donggu Bio Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.